The functional roles of TGF-beta signaling in cardiac lymphangiogenesis during myocardial ischemia
Active Project Grant Awarded Last action
- Award ID
- F31HL186557
- Recipient
-
Temple University-Of The Commonwealth System Of Higher Education UEI QD4MGHFDJKU1
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $73,800
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 0% complete
- Originally
- Place of performance
- Philadelphia, PA 19140, USA
Award details come from USAspending.gov.
Description
- Abstract
- Heart failure caused by myocardial infarction (MI) and ischemia reperfusion injury (IRI) remain the leading cause of death worldwide. Recent studies show that stimulation of lymphatic growth (lymphangiogenesis) after ischemic heart disease improves cardiac function and attenuates adverse cardiac remodeling, linking lymphangiogenesis as a novel target for the treatment of cardiovascular disease. However, post-MI cardiac lymphatics in rodent models or MI patients exhibit abnormal structure, compromising cardiac lymphatic function which give rise to prolonged cardiac inflammation. However, the molecular mechanisms during MI that drive cardiac lymphatic dysfunction remain unknown. My long-term goal is to identify the molecular mechanisms regulating cardiac lymphangiogenesis during the pathogenesis of ischemic heart disease. Transforming growth factor beta (tgfβ), has been identified as a major player driving endmt progression for cardiac fibrosis. However, whether tgfβ signaling regulates post-MI cardiac lymphangiogenesis and lymphatic function is unknown. My preliminary data showed that lymphatic endothelial cell (LEC)-specific TGFΒR2 deficient mice (TGFΒR2ΔLEC/δlec mice) exhibited improved post-MI cardiac function, reduced cardiac fibrosis with increased cardiac lymphangiogenesis, improved lymphatic vessel integrity, and reduced cardiac inflammation. This data strongly suggests tgfβ negatively regulates post-MI cardiac lymphangiogenesis and cardiac function. In vitro treating lecs with tgfβ lead to significantly reduced proliferation, migration, increased apoptosis and disrupted cell VE-cadherin junctions. Rnaseq analysis showed tgfβ promoted a metabolic shift in lecs, significantly downregulating CPT1A and its mediated fatty- acid oxidation (FAO) in tgfβ treated lecs. CPT1A, the rate limiting enzyme of FAO has been shown to be essential for developmental lymphangiogenesis. Interestingly, rescuing CPT1A function using acetylcarnitine rescued tgfβ mediated LEC activities including proliferation, apoptosis, migration, and junction stability in vitro. These data strongly suggest that tgfβ negatively regulates LEC activities by downregulating CPT1A and CPT1A-mediated FAO in lecs. Intriguingly, TGFΒR2ΔLEC/δlec mice displayed increased CPT1A expression in cardiac lymphatics after MI. While targeting CPT1A in TGFΒR2ΔLEC/δlec mice (TGFΒR2ΔLEC/δlec, CPT1A δlec/+) reversed the reduced cardiac fibrosis seen in TGFΒR2ΔLEC/δlec mice after MI. Therefore, i propose that targeting LEC tgfβ signaling can preserve lymphatic CPT1A-mediated FAO, improve lymphatic vessel integrity and function, and promote cardiac repair during MI. In aim 1 of this study, i will utilize mouse genetic tools and in vivo approaches to elucidate the functional role of tgfβ signaling in cardiac lymphangiogenesis during MI. In aim 2 of this study, i will incorporate in vitro cell culture and in vivo animal models to assess the molecular mechanisms of how tgfβ signaling affects LEC activities. Success in these aims will lead to the development of novel therapeutic approaches for treatment of cardiovascular disease.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $36,900 | |
| Amendment | $36,900 | |
| Original award | $0 |
Quick answers
Who received award F31HL186557?
F31HL186557 was awarded to Temple University-Of The Commonwealth System Of Higher Education by National Heart Lung and Blood Institute (National Institutes of Health) on December 15, 2026.
How much is award F31HL186557 worth?
$73,800 has been obligated on F31HL186557.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award